New shot could tame tough eczema in large trial
NCT ID NCT06468956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new way to control this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1819 injection
What this could lead to
If successful, this could provide a new treatment option to control moderate to severe atopic dermatitis, reducing skin inflammation and itch.
What could go wrong
This is still an experimental drug. Even in Phase 3, it may not prove more effective than placebo, and side effects are possible. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, 200040, China